Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...
Roche’s innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, ...
After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback